In a field where hype has often outrun evidence, the 8th International Conference on Stem Cells (ISCSGCON-2026), co-hosted in Hyderabad with Yashoda Hospitals, offered a notably grounded picture of regenerative medicine’s trajectory in India.
Over fifty scientists and clinicians presented data on applications ranging from orthopaedics and cardiometabolic disease to neurodegeneration and chronic inflammatory conditions. The common refrain was caution with momentum: a recognition that stem cell therapies are maturing, but that their credibility hinges on rigorous trials, manufacturing standards, and ethical deployment.
Orthopaedics took centre stage in several plenaries. Teams shared longitudinal outcomes for cartilage repair in knee joints, non-union fracture healing, and early-stage osteoarthritis where cell-based interventions were combined with scaffolds and physiotherapy. While sample sizes were modest, the results suggested meaningful improvements in pain scores and function for select cohorts.
Speakers repeatedly stressed that such therapies are not magic cures or universal replacements for surgery. Rather, they may be best suited as adjuncts or alternatives in carefully stratified patient groups. That message, coming from surgeons themselves, cut against the grain of glossy advertisements that have sometimes oversold regenerative options to desperate patients.
Sessions on chronic systemic diseases examined the immunomodulatory potential of mesenchymal stem cells (MSCs). Presentations on conditions like Crohn’s disease, certain autoimmune syndromes, and complications of diabetes highlighted mixed but intriguing signals. Researchers were candid about negative and equivocal trials, underscoring that null results are as vital to the evidence base as successes.
Running through these clinical discussions was a thread on manufacturing and quality. Representatives from GMP facilities discussed batch variability, cell characterisation assays, and release criteria. Several pointed to the challenge of scaling up production without compromising the subtle biological properties that underlie therapeutic effects.
The partnership with Yashoda Hospitals gave the conference a distinctly translational flavour. Case-based workshops showed how trial protocols are implemented in busy tertiary-care settings, how adverse events are monitored, and how patients are counselled about both potential benefits and unknowns. With Hyderabad already hosting a dense ecosystem of life sciences manufacturers, CROs, and research institutes, the city’s role as a bridge between bench and bedside was on clear display.
Regulation and ethics were not cordoned off into side rooms. A dedicated track on governance debated appropriate evidence thresholds for approving new indications, the line between clinical innovation and experimentation, and mechanisms for cracking down on “stem cell clinics” that offer unproven interventions under the radar. Patient advocates shared stories of individuals who had travelled abroad for costly treatments, only to see little benefit and sometimes harm.
Against this backdrop, ISCSGCON-2026 participants argued for India to position itself as a leader in responsible regenerative medicine rather than a follower in unregulated markets. Proposals included creating national registries of stem cell interventions, incentivising multicentric trials, and building shared biobanking infrastructure to support future research.
By the conference’s close, organisers had sketched a roadmap that leverages Hyderabad’s unique assets: manufacturing muscle, clinical diversity, and academic talent. The vision is of a city that does not merely host trials for overseas companies, but originates protocols, products, and standards that can shape global practice.
In doing so, Hyderabad is doubling down on an identity that has been emerging over the past decade: not just as a vaccine and generics powerhouse, but as India’s regenerative medicine capital—a place where cell therapies are painstakingly translated from possibility to practice.
-Manohar




